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Background: Regadenoson is a vasodilator stress agent that selectively activates the A2A receptor. Compared to
adenosine, regadenoson is easier to administer and results in fewer side effects. Although extensively studied in
patients undergoing nuclear perfusion imaging (MPI), its use for perfusion cardiovascular magnetic resonance (CMR)
is not well described. The aim of this study was to determine the prognostic value of a normal regadenoson
perfusion CMR in patients with known or suspected coronary artery disease.
Methods: Patients with known or suspected coronary artery disease were prospectively enrolled to receive
perfusion CMR (Philips 1.5 T) with regadenoson. Three short-axis slices of the left ventricle (LV) were obtained during
first pass of contrast using a hybrid GRE-EPI pulse sequence (0.075 mmol/kg Gadolinium-DTPA-BMA at 4 ml/sec).
Imaging was performed 1 minute after injection of regadenoson (0.4 mg) and repeated 15 minutes after reversal of
hyperemia with aminophylline (125 mg). Perfusion defects were documented if they persisted for ≥2 frames after
peak enhancement of the LV cavity. CMR was considered abnormal if there was a resting wall motion abnormality,
decreased LVEF (<40%), presence of LGE, or the presence of a perfusion defect during hyperemia. All patients
were followed for a minimum of 1 year for major adverse cardiovascular event (MACE) defined as coronary
revascularization, non-fatal myocardial infarction, and cardiovascular death.
Results: 149 patients were included in the final analysis. Perfusion defects were noted in 43/149 (29%) patients;
59/149 (40%) had any abnormality on CMR. During the mean follow-up period of 24 ± 9 months, 17/149 (11.4%)
patients experienced MACE. The separation in the survival distributions for those with perfusion defects and those
without perfusion defects was highly significant (log-rank p = 0.0001). When the absence of perfusion defects
was added to the absence of other resting CMR abnormalities, the negative predictive value improved from 96%
to 99%.
Conclusion: Regadenoson perfusion CMR provides high confidence for excellent prognosis in patients with
normal perfusion.
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During the last twenty years, perfusion cardiovascular
magnetic resonance (CMR) has evolved from an expe-
rimental diagnostic test performed in only a handful of
academic centers to an established non-invasive tech-
nique for the detection of significant coronary artery
disease. Compared to single-photon emission computed
tomography (SPECT) perfusion imaging, perfusion CMR
provides better spatial resolution without exposing the
patient to ionizing radiation. In addition, the diagnostic
accuracy of perfusion CMR is not limited by attenuation
artifacts, which can confound the interpretation of perfu-
sion SPECT, potentially leading to additional testing [1,2].
Currently, perfusion CMR is most commonly performed
during hyperemia induced by adenosine [3]. A recent
landmark trial comparing the diagnostic performance of
perfusion SPECT with adenosine perfusion CMR reported
superior sensitivity and negative predictive value of the
latter [4]. Other studies have shown that one-year event-
free survival in patients with a normal adenosine perfusion
CMR is 98-100% [5-7].
While the diagnostic [8] and prognostic performance of
adenosine perfusion CMR is excellent, adenosine requires
weight-dependent dosing and is infused continuously via a
separate intravenous line. In addition, adenosine is known
to cause undesirable side effects, such as bronchospasm
and AV nodal block. Regadenoson is a relatively new,
potent vasodilator, but its pharmacokinetics allow for a
simplified fixed-dose single bolus injection, and its select-
ivity of the cardiac A2A adenosine receptor results in fewer
side effects [9]. Indeed, regadenoson is quickly replacing
adenosine as the preferred vasodilator for perfusion
SPECT and has been used for clinical imaging in over 3
million patients [10].
Although there is a significant body of literature re-
garding the performance of regadenoson in perfusion
SPECT [11-13], little is published about its use in
patients undergoing perfusion CMR. Accordingly, in this
study, we sought to 1) assess the safety and tolerability
of regadenoson perfusion CMR, and 2) determine the
prognostic value of a normal regadenoson perfusion
CMR in patients with known or suspected coronary
artery disease.
Methods
Study population and design
From July 2009 through September 2013, 176 patients
referred for perfusion CMR for the evaluation of ische-
mia at a single academic center were prospectively
enrolled. The University of Chicago Institutional Review
Board approved the study, and each patient provided
informed consent. Patients were excluded if they had an
implantable cardioverter-defibrillator, pacemaker or other
standard CMR contraindications, claustrophobia, severereactive airway disease, high-grade AV nodal block, or
GFR < 30 ml/min/1.73 m2. A 12-lead EKG was performed
in all patients prior to CMR imaging to rule out high-
degree AV nodal block. Patients were asked to stop all
anti-anginal medications and caffeine-containing products
12 hours before the CMR exam. Each patient underwent a
focused clinical evaluation in which baseline demograph-
ics, current symptoms, past medical history, and exercise
capacity were assessed and medications documented.
After completion of the perfusion CMR study, patients
were followed for a minimum of 1 year for the primary
composite endpoint of coronary revascularization with per-
cutaneous coronary intervention or coronary artery bypass
grafting, non-fatal myocardial infarction (as documented
by appropriate combination of symptoms, electrocardiog-
raphy, and enzyme changes), and cardiovascular death
(defined as fatal arrhythmias, myocardial infarction, or
heart failure). Since the aim of this study was not to deter-
mine the diagnostic performance of regadenoson perfusion
CMR, patients were referred for invasive coronary angiog-
raphy based on the judgment of the patient’s referring
physician. Follow-up was performed both by reviewing the
medical records and by direct patient contact. Deaths were
confirmed by the Social Security Death Index (SSDI).
Primary event ascertainment was blinded to CMR findings.
CMR Protocol
CMR images were acquired using a 1.5-T scanner
(Achieva, Philips, Best, Netherlands) using a 5-element
phased array cardiac coil. Retrospectively gated cine im-
ages were obtained using a steady-state free precession
(SSFP) sequence (TR 2.9 ms, TE 1.5 ms, flip angle 60°, and
temporal resolution ~40 ms). Standard long-axis views
were obtained, including four-chamber, two-chamber, and
three-chamber images. In addition, one series of short-
axis slices (8 mm thickness, 2 mm gap) from base to apex
was acquired.
In preparation for dynamic contrast-enhanced MPI im-
aging, three short-axis slices were selected representing the
apex, mid, and basal left ventricular myocardium. Stress
images were acquired approximately 60–90 seconds after
the administration of regadenoson (Lexiscan, 0.4 mg I.V.;
Astellas Pharma). During peak vasodilator stress, gadolin-
ium-DTPA-BMA (Omniscan™, 0.075 mmol/kg at 4 ml/sec,
I.V.) was given, and images were acquired for 50–70
consecutive heartbeats using a hybrid gradient echo/echo
planar imaging sequence (voxel size ~2.5×2.5 mm, slice
thickness 10 mm, flip angle 20°, repetition time 5.9 ms,
echo time 2.5 ms, EPI factor 5, delay time 80 ms, and
SENSE factor 1.3). Immediately after images were ob-
tained, aminophylline 75–125 mg was injected intra-
venously. The same pulse sequence was repeated
15 minutes later to obtain perfusion images under
resting conditions.
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same short- and long-axis views were obtained 5 minutes
after the second injection of contrast using a T1-
weighted gradient echo pulse sequence with a phase
sensitive inversion recovery reconstruction (TR 4.5 ms,
TE 2.2 ms, TI 250-300 ms, flip angle 30°, flip angle 5°,
voxel size 2×2×10 mm, SENSE factor 2). An inversion
time between 250 and 300 ms was used to achieve
nulling of normal myocardium. Heart rate, blood pressure,
and symptoms were monitored throughout the entire
examination.
CMR image analysis
Images were analyzed using commercial software (Philips
ViewForum, Best, Netherlands). Short-axis slices were
used to measure left ventricular end-diastolic (first cine
phase of the R wave triggered acquisition) and end-
systolic (image phase with the smallest ventricular cavity
area in the majority of slices) volumes, mass, and ejection
fraction by the Simpson method of disks [14]. All volumes
and masses were indexed for body surface area. Detection
of regional wall motion abnormalities was primarily based
upon the short-axis view and confirmed in orthogonal
long-axis views.
Perfusion images were visually assessed by a cardiologist
with expertise in stress CMR and myocardial perfusion
imaging (ARP). Stress-induced perfusion defects were de-
fined as decreased signal intensity of the subendocardium
in a coronary distribution during stress, involving ≥ 25%
wall thickness, and persisting for ≥ 2 consecutive frames
following peak enhancement of the left ventricular cavity.
Resting images were used to exclude artifacts. LGE of the
myocardium was also visually assessed and considered to
be present if the signal intensity in the myocardium was
greater than or equal to that seen in the blood pool in 2
adjacent slices or transverse imaging planes.
Statistical analysis
Categorical variables were expressed as percentages and
continuous variables as mean ± SD. Independent sample
(unpaired) student’s t-test (equal variances not assumed)
was used to compare the means of normally distributed
continuous variables in those patients with and without
adverse outcomes. The Mann–Whitney U test was used
to compare the means for non-normally distributed
variables. Categorical variables were compared using
Fisher’s Exact test. P values <0.05 were considered statis-
tically significant.
Survival analysis was accomplished using Kaplan-
Meier curves, and differences between observed and
predicted primary outcome distributions were assessed
using the log-rank test. Three Kaplan-Meier graphs were
generated. The first graph compared patients with per-
fusion defects to patients without perfusion defects. Thesecond graph compared patients with resting CMR
abnormalities (LGE, LVEF < 40%, and/or regional wall
motion abnormalities) to patients with normal resting
CMR exams. The third graph compared patients with
and without a combination of perfusion defects and
resting CMR abnormalities. All statistical analyses were




A total of 176 patients were enrolled in the study. Five
patients were unable to complete the CMR exam due to
previously unknown claustrophobia and two due to
technical problems during the examination. Four patients
had non-diagnostic perfusion studies due to severe dark
rim artifact or poor image quality due to shift in coil
position and were excluded from the final analysis.
The remaining 165 patients successfully completed
regadenoson perfusion CMR. All patients were followed
using 1) telephone contact, 2) communication with their
physician, and/or 3) medical record review. Sixteen pa-
tients were lost to follow-up during the mean follow-up
period of 24 ± 9 months. Thirteen of these patients had
a negative perfusion study and 3 patients had a perfusion
defect. None of these patients were reported as deceased
when cross-referenced against the SSDI.
Final analysis was performed on 149 patients. The
majority of patients (97%) had one or more cardiac risk
factors. The mean age was 56 ± 15 years, and the mean
body mass index was 29 ± 7 kg/m2. Patients who met
the primary composite endpoint were significantly older
and were more likely to have hypertension and left
ventricular dysfunction. Patient characteristics are listed
in Table 1.
Eleven percent of the patients (17/149) reached the
primary composite endpoint of MACE (Table 1). Of these
patients, 15 received coronary revascularization and 2 had
sudden cardiac death. Two patients who died of non-
cardiac complications (1 of lymphoma and 1 of sepsis due
to gangrene) were censored for MACE evaluation.
Regadenoson perfusion CMR results
The average LVEF was 58 ± 12%. Eleven patients had an
LVEF <40%. Perfusion defects during hyperemia were
present in 43/149 (29%) of patients (Figure 1). Regional
wall motion abnormalities were present in 20/149 (13%),
and LGE was present in 33/149 (22%). Of the patients
with evidence of LGE, 20 had LGE in a pattern con-
sistent with prior myocardial infarction, and 13 had LGE
in a pattern atypical for prior myocardial infarction.
Atypical patterns of LGE consisted of focal areas of
enhancement that did not involve the subendocardium
or follow a coronary distribution.
Table 1 Baseline patient characterictics
Baseline All patients (n = 150) Adverse outcome (n = 17) No adverse outcome (n = 133) p-value
Females 66 (44) 6 (35) 60 (45) 0.45
History of CAD 45 (30) 9 (53) 36 (27) 0.06
History of CHF 24 (16) 6 (35) 18 (14) 0.10
History of smoking 53 (35) 10 (59) 43 (32) 0.06
Diabetes mellitus 44 (29) 9 (53) 35 (226) 0.06
Hypertension 90 (60) 15 (88) 75 (56) 0.01
Hyperlipidemia 111 (74) 13 (76) 98 (74) 0.88
Stroke 10 (7) 1 (6) 9 (7) 0.93
Peripheral vascular disease 7 (5) 2 (12) 5 (4) 0.35
LVEF (%) 58.0 ± 11.7 50.1 ± 16.6 59.5 ± 10.5 0.04
BMI (kg/m2) 29.0 ± 7.0 25.2 ± 9.50 29.0 ± 6.3 0.13
Age (years) 56.0 ± 14.7 65.9 ± 10.8 54.4 ± 14.6 0.01
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The hemodynamic effects of regadenoson administration
are summarized in Table 2. Heart rate increased signifi-
cantly by an average of 36 beats/min during hyperemia
with regadenoson (p < 0.01). The maximal increase in
heart rate occurred approximately 60 seconds after in-
jection of regadenoson. A heart rate of >100 beats/min
was noted in 60/149 (40%) patients, with a maximal
heart rate of 151 beats/min. The mean systolic and
diastolic blood pressure decreased slightly between base-
line conditions and hyperemia. During rest perfusion,
the average heart rate returned to near-baseline.
Safety and tolerability of regadenoson
There were no significant arrhythmias noted by rhythm
strip monitoring during hyperemia. Two patients devel-
oped an infiltration of their intravenous line and returned
on a later date to complete the exam. Overall, 127/149
(85%) of patients experienced symptoms associated withFigure 1 Perfusion defect on regadenoson perfusion cardiovascular m
inferior, inferolateral, and inferoseptal wall hypoperfusion (white arrows) on
reveals two significant stenoses in the proximal and mid-right coronary artregadenoson administration (Figure 2). The four most
common side effects included shortness of breath (32%),
flushing (23%), chest discomfort (15%), and palpitations
(15%). There was no evidence of bronchospasm. The ma-
jority of symptoms were reportedly mild and diminished
by the end of the study. One patient experienced persistent
headache and abdominal pain after the injection of regade-
noson despite the administration of 125 mg of aminophyl-
line. This patient had stress-induced perfusion defects and
subsequently underwent coronary revascularization.
Prognosis
During a follow-up of 24 ± 9 months, the primary compos-
ite endpoint occurred in 5/106 (4.7%; 2.4%/year) patients
with no evidence of perfusion defect on regadenoson
perfusion CMR study. The absence of perfusion defects on
regadenoson perfusion CMR resulted in a negative predict-
ive value of 96%, and the separation in the survival distri-
butions for those with perfusion defects and those withoutagnetic resonance. Short axis image of a patient with extensive
ly during hyperemia. Subsequent cardiac catheterization in this patient
ery.
Table 2 Hemodynamic effects of regadenoson during CMR-MPI
Hemodynamics Baseline Regadenoson p-value (Baseline vs. Regadenoson) Recovery p-value (Regadenoson vs. Recovery)
Heart rate (bpm) 69 ± 12 97 ± 15.0 <0.01 70 ± 12.4 <0.01
Systolic blood
pressure (mmHg)
128 ± 19.4 126 ± 18.9 0.48 125 ± 18.4 0.48
Diastolic blood
pressure (mmHg)
66 ± 12.3 62 ± 13.3 0.01 62 ± 12.1 0.96
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the absence of perfusion defects was added to the absence
of other resting CMR abnormalities (LVEF < 40%, regional
wall motion abnormalities, and presence of LGE), the
negative predictive value improved from 96% to 99%.
Kaplan Meier analysis shows an increasingly significant
separation in survival curves between patients with and
without CMR resting abnormalities alone (Figure 4) and
patients with and without CMR resting abnormalities plus
perfusion defects (Figure 5).
The presence of perfusion defects on regadenoson
perfusion CMR was a statistically significant predictor of
the primary composite endpoint (hazard ratio 6.4; 95%
CI 2.25-18.2; p = 0.001). LVEF < 40% (hazard ratio 6.4;
95% CI 2.28-18.5, p = 0.001), the presence of LGE
(hazard ratio 3.45; 95% CI 1.33-8.95, p = 0.011), and the
presence of any resting regional wall motion abnormality
(hazard ratio 3.12; 95% CI 1.10-8.88, p = 0.033) were also
statistically significant for predicting the primary com-
posite endpoint.
Discussion
We studied the safety and tolerability of regadenoson
perfusion CMR and determined the prognostic value of
a normal study. Our results revealed that regadenoson
perfusion CMR can be performed safely and its side
effects were tolerated by nearly all (99%) of our patients.Figure 2 Common side effects of regadenoson. Percentage of
patients who experienced one or more side effects after
regadenoson administration.This study demonstrated that, not only does a normal
regadenoson perfusion CMR identify a cohort of patients
who are unlikely to have MACE during the subsequent
24 ± 9 months, but a strategy that incorporates as-
sessment of regadenoson-induced perfusion defects with
resting CMR abnormalities (LVEF < 40%, presence of
LGE, regional wall motion abnormalities) provides a
negative predictive value of 99%.
Regadenoson characteristics
Regadenoson is the first selective vasodilator approved
by the FDA and has comparable vasodilator efficacy
when compared to adenosine [15]. Unlike adenosine,
studies have shown that regadenoson, because of its
highly selective A2A receptor-binding properties, results
in milder side effects, fewer cases of bronchospasm, and
rarely any instances of high-degree AV nodal block
[10-12,16].
In the ADVANCE MPI Phase III trials evaluating the
effects of intravenous regadenoson in humans undergo-
ing perfusion SPECT, the investigators compared a
summed symptom score of flushing, chest pain, and
dyspnea in patients receiving both adenosine and rega-
denoson and found that regadenoson resulted in signifi-
cantly lower overall scores [12,16]. In addition, the same
investigators developed tolerability questionnaires asking
how comfortable patients felt with each drug and found
that patients were significantly more comfortable with
regadenoson compared to adenosine. Furthermore, no
major adverse events occurred with the use of regadeno-
son in any of these studies.
Consistent with these studies, we found that the
majority of patients experienced only mild side effects
including shortness of breath, chest pain, palpitations,
and flushing, which subsided by the end of the CMR
exam. Although studies have reported a greater inci-
dence of gastrointestinal symptoms and headaches with
regadenoson compared to adenosine, we found these
symptoms to be rare. In addition, there were no episodes
of bronchospasm, life-threatening arrhythmias, or any
other MACE during or within 24 hours of the test.
Furthermore, the simplicity of regadenoson admi-
nistration makes it an attractive vasodilator to use in the
CMR environment. Due to its longer half-life (33–
108 min vs. 2–10 sec) [9] and the fact that neither its
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Figure 3 Prognostic value of perfusion information. Event-free survival for patients with perfusion defects compared to patients without
perfusion defects.
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injected as a fixed-dose unit bolus. This decreases the
chances of weight-dependent dosing errors and obviates
the need for a second intravenous line or a CMR-
compatible infusion pump.
Prognostic value of normal regadenoson perfusion CMR
In our study, only 5/106 (4.6%; 2.4%/year) patients with
normal perfusion CMR subsequently underwent coronary


























Figure 4 Prognostic value of resting CMR abnormalities. Event free sur
presence of LGE, and regional wall motion abnormalities) compared to pator cardiac death. Two patients, who initially presented
with atypical chest pain, returned less than 1 year after a
normal perfusion CMR test with typical angina. Two
patients had multivessel coronary artery disease and 1
patient had end-stage liver disease and a significant
coronary lesion.
It has been previously shown that the burden of
ischemia may be significantly underestimated by visual as-
sessment of perfusion defects in patients with multi-vessel
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91 71 14 0No Abnormalities
Number at risk
0 500 1000 1500
Days After Enrollment
No Resting CMR Abnormalities or Perfusion Defects
Resting CMR Abnormalities and Perfusion Defects
Figure 5 Incremental prognostic value of adding perfusion data to other CMR findings. Patients with resting CMR abnormalities and stress
perfusion defects compared to patients without CMR abnormalities or perfusion defects. CMR = cardiovascular magnetic resonance; LVEF = left
ventricular ejection fraction; LGE = late gadolinium enhancement.
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in patients with liver disease is questionable given the
underlying hyperemic state of these patients [19]. Regard-
less, the negative predictive value of 96% is consistent with
event-free survival rates in patients with normal adenosine
perfusion CMR [5-7,20-22] and the separation in the
survival distributions for those with perfusion defects and
those without (Figure 3) was highly significant (log-rank
p = 0.0001).
Added prognostic value of regadenoson MPI to a
comprehensive resting CMR study
One of the most powerful attributes of CMR imaging in
patients with known or suspected coronary artery
disease is that it provides information on a multitude of
known prognostic parameters including myocardial scar/
viability, LV systolic function, and wall motion abnor-
malities. These parameters clearly help in identifying
patients who are at risk for MACE. This study found
that the addition of regadenoson perfusion imaging to
these other parameters improves the prognostic power
of CMR increasing the negative predictive value from
96% to 99%. Kaplan-Meier analysis shows that the com-
bination of perfusion data to CMR resting assessment
improves identification of those patients who will have
MACE in the next 24 ± 9 months and those who will
not (Figure 5). The incremental value of regadenoson
perfusion CMR is that a greater number of patients
without perfusion defects can be reassured about their
cardiovascular future.
It has previously been shown that the addition of
adenosine perfusion CMR to a comprehensive CMRstudy significantly enhances risk stratification. Steel et al.
reported that the absence of reversible perfusion defects
combined with the absence of LGE provided the lowest
annual event rate compared to either finding in isolation
[20]. A recent study examined the incremental prognos-
tic value of cardiac clinical risk factors, LGE, LVEF, and
aortic blood flow to adenosine perfusion in over 900
patients and found that each variable provided valuable
complimentary information [23]. The absence of LGE
and perfusion defects along with a normal LVEF ensured
the lowest cardiac event rate. Our results are in line with
these previous publications and extend their findings to
a wider range of vasodilators.
Technical considerations when using regadenoson
perfusion CMR
While regadenoson did not significantly affect blood
pressure, the average heart rate increased by 36 bpm,
and 40% of patients developed tachycardia. Since the
blood pressure decreased only minimally, the mechan-
ism of regadenoson-induced tachycardia is thought to be
secondary to the direct release of norepinephrine and
epinephrine through stimulation of post-ganglionic re-
ceptors, rather than a strictly baroreflexive response
[24]. Other studies have also noted a 21–27 bpm increase
in heart rate with regadenoson [10-12,15,16,25], and
several of these studies reported that the change in heart
rate was significantly higher than that seen with adenosine
[12,15,16]. Although the change in heart rate is typically
well-tolerated by patients, fast heart rates can exacerbate
dark rim artifacts and may prevent image acquisition
during every heart beat making image interpretation more
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issue in patients with elevated resting heart rates.
Another technical issue concerns the longer half-life of
regadenoson and the stress-rest protocol we performed.
Studies have shown that 0.4 mg of regadenoson will
continue to induce a greater than 2-fold increase in
coronary blood flow for up to 8.5 minutes [25]. When
100 mg of aminophylline was given, the hyperemia was
dramatically blunted without any effect on the heart
rate. However, as we have shown in a previous study,
even after giving each patient 125 mg of aminophylline
after stress perfusion imaging, some vasodilator effects
of regadenoson remain during acquisition of the resting
images [27].
Finally, although in perfusion SPECT, radioactive tracer
is usually injected approximately 20 seconds after regade-
noson is given, maximal coronary blood flow was reported
to occur, on average, 102 seconds after regadenoson
administration [28]. We, therefore, started perfusion im-
aging approximately 60–90 seconds after regadenoson
was injected. This allowed enough time to administer the
medication and return to the control room to initiate
scanning.
Limitations
This study has several limitations. First, coronary revas-
cularization drove the majority of clinical endpoints and
the decision to proceed with catheterization was likely
influenced by the results of the perfusion CMR test.
However, while the presence of perfusion defects may
have influenced the decision to refer the patient for
coronary angiography, the decision to revascularize was
made at the time of the catheterization. Furthermore, we
have shown that a significant number of patients with-
out perfusion defects did well and only rarely revascu-
larized over an average of 2 years and, thus, avoided
unnecessary invasive testing. Second, we did not
determine the sensitivity or specificity of regadenoson
perfusion CMR to detect coronary stenoses, since only a
small group of patients underwent coronary angiog-
raphy. Third, although every patient was followed for a
minimum of 1 year and had known or suspected coron-
ary artery disease, there were a low number of car-
diovascular events in this study. Finally, although
aminophylline was given only to reverse the hyperemic
effects of regadenoson, it is likely that it also helped
mitigate some of the side effects. However, even before
we administered the aminophylline, many patients re-
ported that their symptoms had already started to abate.
Conclusion
Vasodilator perfusion CMR is increasingly being used to
evaluate patients with known or suspected coronary
artery disease. Currently, adenosine is the most commonlyused vasodilator, but it is cumbersome to administer and
can be difficult for some patients to tolerate. We have
demonstrated that, not only is regadenoson safe, well-
tolerated, and easy to administer, but the prognostic
performance of a negative regadenoson perfusion CMR
study is comparable to that previously described for
adenosine perfusion CMR. Furthermore, the addition of
regadenoson stress imaging to information regarding
LVEF, LGE, and regional wall motion further improves
identification of those patients at lowest risk for future
cardiac events. Given these characteristics, regadenoson is
a reasonable and attractive alternative to adenosine for
vasodilator stress perfusion CMR studies.
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